Treatment with neoadjuvant chemotherapy plus immunotherapy (CH-I) is of key importance for the treatment of patients with locally advanced and metastatic NMSC. However, we lack biomarkers capable of discriminating between patients who benefit from the CH-I combination and those who do not.

The main objective of the project is to obtain a new tool for stratifying the risk of relapse/progression in patients with microcytic lung cancer treated with chemoimmunotherapy using new molecular biomarkers.